Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Aug;18(4):347-60.
doi: 10.1007/BF01062273.

Experimental design and efficient parameter estimation in population pharmacokinetics

Affiliations

Experimental design and efficient parameter estimation in population pharmacokinetics

M K al-Banna et al. J Pharmacokinet Biopharm. 1990 Aug.

Abstract

A computer simulation technique used to evaluate the influence of several aspects of sampling designs on the efficiency of population pharmacokinetic parameter estimation is described. Although the simulations are restricted to the one-compartment one-exponential model, they provide the basis for a discussion of the structural aspects involved in designing a population study. These aspects include number of subjects required, number of samples per subject, and timing of these samples. Parameter estimates obtained from different sampling schedules based on two- and three-point designs are evaluated in terms of accuracy and precision. These simulated data sets include noise terms for both inter- and intraindividual variability. The results show that the population fixed-effect parameters (mean clearance and mean volume of distribution) for this simple pharmacokinetic model are efficiently estimated for most of the sampling schedules when two or three points are used, but the random-effect parameters (describing inter- and intraindividual variability) are inaccurate and imprecise for most of the sampling schedules when only two points are used. This drawback was remedied by increasing the number of data points per individual to three.

PubMed Disclaimer

References

    1. J Pharm Sci. 1973 Oct;62(10):1579-89 - PubMed
    1. J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19 - PubMed
    1. Am J Physiol. 1981 May;240(5):R259-65 - PubMed
    1. Endocrinology. 1982 Jul;111(1):108-17 - PubMed
    1. J Pharmacokinet Biopharm. 1981 Dec;9(6):739-56 - PubMed

Publication types